The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
 
Sibylle Loibl
Research Funding - AstraZeneca (Inst); Celgene (Inst)
 
Michael Untch
No Relationships to Disclose
 
Nicole Burchardi
No Relationships to Disclose
 
Jens Bodo Huober
Consulting or Advisory Role - AstraZeneca; Celgene
Research Funding - Celgene
 
Jens Uwe Blohmer
No Relationships to Disclose
 
Eva-Maria Grischke
No Relationships to Disclose
 
Jenny Furlanetto
No Relationships to Disclose
 
Hans Tesch
Honoraria - AstraZeneca; Celgene
Consulting or Advisory Role - AstraZeneca; Celgene
 
Claus Hanusch
No Relationships to Disclose
 
Mahdi Rezai
No Relationships to Disclose
 
Christian Jackisch
No Relationships to Disclose
 
Wolfgang D Schmitt
No Relationships to Disclose
 
Gunter Von Minckwitz
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Myriad Genetics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Teva (Inst); Vifor Pharma (Inst)
 
Jörg Thomalla
No Relationships to Disclose
 
Sherko Kummel
Honoraria - Amgen; Celgene; Genomic Health; Novartis; Roche
Consulting or Advisory Role - Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Celgene; Roche
 
Beate Rautenberg
Research Funding - AstraZeneca (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Medivation (Inst); Novartis (Inst); Roche (Inst)
 
Peter A. Fasching
Honoraria - Amgen; Novartis; Pfizer; Roche
Consulting or Advisory Role - Novartis; Pfizer; Roche
Research Funding - Amgen (Inst); Novartis (Inst)
 
Kerstin Rhiem
Consulting or Advisory Role - AstraZeneca
 
Carsten Denkert
No Relationships to Disclose
 
Andreas Schneeweiss
Honoraria - Celgene; Roche